| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 |
|---|---|---|---|---|---|---|
Revenues [Abstract] | ||||||
Product sales, net | ||||||
2,108 | - | - | - | - | - | - |
Costs and operating expenses: | ||||||
Cost of sales | ||||||
48 | - | - | - | - | - | - |
Research and development | ||||||
174,556 | 131,307 | 87,807 | 62,163 | 36,657 | 16,324 | 12,855 |
Selling, general and administrative | ||||||
117,088 | 51,435 | 31,438 | 20,964 | 9,671 | 3,855 | 2,309 |
Gain on lease modification | ||||||
8,301 | - | - | - | - | - | - |
Total costs and operating expenses | ||||||
283,391 | 182,742 | 119,245 | 83,127 | 46,393 | 20,511 | 15,663 |
Related party expenses | ||||||
- | - | - | - | 65 | 332 | 499 |
Loss from operations | ||||||
-281,283 | -182,742 | -119,245 | -83,127 | -46,393 | -20,511 | -15,663 |
Interest income, net | ||||||
14,697 | 8,618 | 2,555 | 659 | 33 | 1 | 2 |
Change in fair value of Series A redeemable convertible preferred stock liability | ||||||
- | - | - | - | - | 297 | -2,500 |
Other expenses, net | ||||||
180 | 69 | 334 | - | - | - | - |
Net loss | ||||||
-266,766 | -174,193 | -117,024 | -82,468 | -46,360 | -20,807 | -18,116 |
Other comprehensive income: | ||||||
Net unrealized gain on marketable securities, net of tax | ||||||
802 | 288 | -170 | -166 | - | - | - |
Comprehensive loss | ||||||
-265,964 | -173,905 | -117,194 | -82,634 | -46,360 | -20,807 | -18,116 |
Net loss attributable to common stockholders | ||||||
- | - | - | - | - | -23,772 | -19,851 |
Basic and diluted net loss per common share | ||||||
-4.57 | -3.41 | -2.76 | -2.48 | -3.95 | -14.20 | -16.14 |
Weighted-average number of shares used in computing basic and diluted net loss per common share | ||||||
58,321 | 51,150 | - | 33,207 | 12,806 | 1,673 | 1,230 |